Latest stories on NGEN
NervGen appoints Sam Jackson as chief medical officer
TipRanks56 · neutralproduct/pr
NervGen Pharma appoints Sam Jackson as chief medical officer
The Fly53 · neutralgeneral
NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
GlobeNewswire58 · neutralproduct/pr
NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
Business Insider58 · neutralproduct/pr
NervGen Pharma (NGEN) Reports Narrower Loss but Rising Net Deficit Amid R&D Spend Surge
GuruFocus42 · neutralearnings
NervGen Pharma reports results
Seeking Alpha42 · neutralearnings
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
Business Insider64 · neutralearnings
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire64 · neutralearnings
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
GlobeNewswire74 · bullishproduct/pr
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
StockTitan74 · bullishproduct/pr
NervGen Pharma doses first participant in RESTORE trial
The Fly58 · neutralproduct/pr
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
GlobeNewswire63 · neutralproduct/pr
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
Business Insider63 · neutralproduct/pr
NervGen Pharma: The Upside Is Large, But Phase 3 Decides Everything
Seeking Alpha58 · neutralproduct/pr
NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript
Seeking Alpha56 · neutralproduct/pr
NervGen Pharma to restate previously filed financial statements
The Fly34 · bearishgeneral
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
StockTitan48 · neutralgeneral
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
Business Insider48 · neutralgeneral
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
GlobeNewswire48 · neutralgeneral
Veea, NovaGen announce potential merger
The Fly55 · neutralm&a
NervGen to Host Inaugural R&D Day on September 30, 2026
Business Insider56 · neutralproduct/pr
NG Energy International reports Q2 results
Seeking Alpha50 · neutralearnings
NervGen Pharma GAAP EPS of -C$0.37
Seeking Alpha34 · bearishearnings
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire55 · neutralgeneral
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
Business Insider55 · neutralgeneral